A polypeptide comprising a variant of a starting amino acid sequence, wherein the polypeptide binds to and/or disaggregates amyloid; wherein the starting amino acid sequence is amino acids 1-217 of SEQ ID NO:1 or amino acids 1-217 of SEQ ID NO:2; wherein the variant differs from the starting amino acid sequence by removal of the putative glycosylation signal at amino acids 39-41, wherein removal of the putative glycosylation signal is achieved by amino acid substitution of one or more of N39, A40 and/or T41; and wherein the variant optionally and additionally differs from the starting amino acid sequence by one or more of: (a) one or more modifications selected from: (i) substitution of VVV at amino acids 43-45 with AAA; (ii) substitution C53W; (iii) deletion of amino acids 96-103; (iv) substitution of QPP at amino acids 212-214 with AGA; (v) substitutions W181A, F190A and F194A; (vi) deletion of amino acid 1; (vii) deletion of amino acids 1 and 2; and (viii) addition of a N-terminal methionine residue; and (b) decreased immunogenicity resulting from 1 to 9 amino acid substitutions selected from: Amino Acid # Amino Acid present in the Starting Amino Acid Sequence Amino Acid Substitutions 48 G H, K, R, S, T, D, P 50 E G, H, K, P, R 51 T G, H, K, R, P, Q, N, W 53 C F, H, K, N, Q, R, W, Y 54 Y G, H, K, R, P 56 T G, H, K, R, P 135 M A, D, G, K, N, T, H, R, C, E, P, Q, S 137 Q D, E 138 N D, E, G, H, P, Q, S, T 140 R D, E, H, Q, A, G, M, N, P, S, Y 141 F D, E, G, N, P, Q, Y 143 N A, G 173 S G, P, K, D, H, R, T 174 K R 175 A G, H, K, P, R 176 M G, H, K, N, R, P, Q, W 178 D G, N, Q, S, T, F, H, K, R, W, Y 179 A H, K, P, R 181 W G, H, K, R, P wherein when the starting amino acid sequence is amino acids 1-217 of SEQ ID NO: 1, any of the 1 to 9 amino acid substitutions in (b) may additionally be selected from a substitution of V215 with S, T, C, D, E, F, H, K, N, P, Q, or R. wherein the polypeptide binds to and/or disaggregates amyloid; wherein the starting amino acid sequence is amino acids 1-217 of SEQ ID NO:1 or amino acids 1-217 of SEQ ID NO:2; wherein the variant differs from the starting amino acid sequence by removal of the putative glycosylation signal at amino acids 39-41, wherein removal of the putative glycosylation signal is achieved by amino acid substitution of one or more of N39, A40 and/or T41; and wherein the variant optionally and additionally differs from the starting amino acid sequence by one or more of: (a) one or more modifications selected from: (i) substitution of VVV at amino acids 43-45 with AAA; (ii) substitution C53W; (iii) deletion of amino acids 96-103; (iv) substitution of QPP at amino acids 212-214 with AGA; (v) substitutions W181A, F190A and F194A; (vi) deletion of amino acid 1; (vii) deletion of amino acids 1 and 2; and (viii) addition of a N-terminal methionine residue; and (b) decreased immunogenicity resulting from 1 to 9 amino acid substitutions selected from: Amino Acid # Amino Acid present in the Starting Amino Acid Sequence Amino Acid Substitutions 48 G H, K, R, S, T, D, P 50 E G, H, K, P, R 51 T G, H, K, R, P, Q, N, W 53 C F, H, K, N, Q, R, W, Y 54 Y G, H, K, R, P 56 T G, H, K, R, P 135 M A, D, G, K, N, T, H, R, C, E, P, Q, S 137 Q D, E 138 N D, E, G, H, P, Q, S, T 140 R D, E, H, Q, A, G, M, N, P, S, Y 141 F D, E, G, N, P, Q, Y 143 N A, G 173 S G, P, K, D, H, R, T 174 K R 175 A G, H, K, P, R 176 M G, H, K, N, R, P, Q, W 178 D G, N, Q, S, T, F, H, K, R, W, Y 179 A H, K, P, R 181 W G, H, K, R, P wherein when the starting amino acid sequence is amino acids 1-217 of SEQ ID NO: 1, any of the 1 to 9 amino acid substitutions in (b) may additionally be selected from a substitution of V215 with S, T, C, D, E, F, H, K, N, P, Q, or R. (a) one or more modifications selected from: (i) substitution of VVV at amino acids 43-45 with AAA; (ii) substitution C53W; (iii) deletion of amino acids 96-103; (iv) substitution of QPP at amino acids 212-214 with AGA; (v) substitutions W181A, F190A and F194A; (vi) deletion of amino acid 1; (vii) deletion of amino acids 1 and 2; and (viii) addition of a N-terminal methionine residue; and (i) substitution of VVV at amino acids 43-45 with AAA; (ii) substitution C53W; (iii) deletion of amino acids 96-103; (iv) substitution of QPP at amino acids 212-214 with AGA; (v) substitutions W181A, F190A and F194A; (vi) deletion of amino acid 1; (vii) deletion of amino acids 1 and 2; and (viii) addition of a N-terminal methionine residue; and (b) decreased immunogenicity resulting from 1 to 9 amino acid substitutions selected from: Amino Acid # Amino Acid present in the Starting Amino Acid Sequence Amino Acid Substitutions 48 G H, K, R, S, T, D, P 50 E G, H, K, P, R 51 T G, H, K, R, P, Q, N, W 53 C F, H, K, N, Q, R, W, Y 54 Y G, H, K, R, P 56 T G, H, K, R, P 135 M A, D, G, K, N, T, H, R, C, E, P, Q, S 137 Q D, E 138 N D, E, G, H, P, Q, S, T 140 R D, E, H, Q, A, G, M, N, P, S, Y 141 F D, E, G, N, P, Q, Y 143 N A, G 173 S G, P, K, D, H, R, T 174 K R 175 A G, H, K, P, R 176 M G, H, K, N, R, P, Q, W 178 D G, N, Q, S, T, F, H, K, R, W, Y 179 A H, K, P, R 181 W G, H, K, R, P